Wei-Wu He Ph.D.
Net Worth

Last updated:

What is Wei-Wu He Ph.D. net worth?

The estimated net worth of Dr. Wei-Wu He Ph.D. is at least $12,052,050 as of 15 Jun 2022. He owns shares worth $1,398,680 as insider and has received compensation worth at least $10,653,370 in CASI Pharmaceuticals, Inc..

What is the salary of Wei-Wu He Ph.D.?

Dr. Wei-Wu He Ph.D. salary is $819,490 per year as Chairman & Chief Executive Officer in CASI Pharmaceuticals, Inc..

How old is Wei-Wu He Ph.D.?

Dr. Wei-Wu He Ph.D. is 60 years old, born in 1965.

What stocks does Wei-Wu He Ph.D. currently own?

As insider, Dr. Wei-Wu He Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
CASI Pharmaceuticals, Inc. (CASI) Chairman & Chief Executive Officer 644,553 $2.17 $1,398,680

What does CASI Pharmaceuticals, Inc. do?

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

CASI logo
CASI
CASI Pharmaceuticals, Inc.
$2.17

Wei-Wu He Ph.D. insider trading

CASI Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 50,000 $3.18 $159,000
Purchase
Common Stock 2,096 $3.06 $6,414
Purchase
Common Stock 36,058 $2.97 $107,092
Purchase
Common Stock 200,000 $0.98 $196,000
Purchase
Common Stock 200,000 $0.99 $198,000
Purchase
Common Stock 180,000 $1.26 $226,800
Purchase
Common Stock 300,000 $1.29 $387,000
Purchase
Common Stock 3,000,000 $2.05 $6,150,000
Purchase
Common Stock 100,000 $2.18 $218,000
Purchase
Common Stock 127,471 $2.12 $270,239
Purchase
Common Stock 4,152,426 $1.9 $7,889,609
Purchase
Common Stock 4,152,426 $1.9 $7,889,609
Purchase
Common Stock 56,464 $2.37 $133,820
Purchase
Common Stock 29,801 $2.03 $60,496
Purchase
Common Stock 338,932 $2.02 $684,643
Purchase
Common Stock 100,000 $1.82 $182,000
Purchase
Common Stock 6,880 $2.08 $14,310
Purchase
Common Stock 328,095 $2.09 $685,719
Purchase
Common Stock 196,398 $1.94 $381,012
Purchase
Common Stock 234,488 $1.57 $368,146
Purchase
Common Stock 501,322 $1.52 $762,009
Purchase
Common Stock 264,192 $1.5 $396,288
Purchase
Common Stock 20,000 $3.2 $64,000
Purchase
Common Stock 160,000 $3.17 $507,200
Purchase
Common Stock 3,086,419 $3.24 $9,999,998
Purchase
Common Stock 100,000 $1.95 $195,000
Purchase
Common Stock 100,000 $1.86 $186,000
Purchase
Common Stock 100,000 $1.86 $186,000
Purchase
Common Stock 34,002 $1.78 $60,524
Purchase
Common Stock 173,500 $1.75 $303,625
Purchase
Common Stock 127,702 $1.49 $190,276
Purchase
Common Stock 187,625 $1.22 $228,903
Purchase
Common Stock 1,871,605 $1.19 $2,227,210
Purchase
Common Stock 441,072 N/A N/A

CASI Pharmaceuticals key executives

CASI Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: